GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Shiller PE Ratio

Cara Therapeutics (Cara Therapeutics) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cara Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cara Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Shiller PE Ratio Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cara Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Cara Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Shiller PE Ratio falls into.



Cara Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cara Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cara Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.6/129.4194*129.4194
=-0.600

Current CPI (Dec. 2023) = 129.4194.

Cara Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.220 99.695 -0.286
201406 -0.160 100.560 -0.206
201409 -0.290 100.428 -0.374
201412 -0.180 99.070 -0.235
201503 -0.210 99.621 -0.273
201506 -0.250 100.684 -0.321
201509 -0.190 100.392 -0.245
201512 -0.350 99.792 -0.454
201603 -0.390 100.470 -0.502
201606 -0.480 101.688 -0.611
201609 -0.420 101.861 -0.534
201612 -0.810 101.863 -1.029
201703 -0.810 102.862 -1.019
201706 -0.290 103.349 -0.363
201709 -0.380 104.136 -0.472
201712 -0.430 104.011 -0.535
201803 -0.510 105.290 -0.627
201806 -0.520 106.317 -0.633
201809 -0.510 106.507 -0.620
201812 -0.520 105.998 -0.635
201903 -0.560 107.251 -0.676
201906 -0.580 108.070 -0.695
201909 -0.740 108.329 -0.884
201912 -0.610 108.420 -0.728
202003 -0.620 108.902 -0.737
202006 -0.540 108.767 -0.643
202009 -0.350 109.815 -0.412
202012 1.690 109.897 1.990
202103 -0.470 111.754 -0.544
202106 -0.610 114.631 -0.689
202109 -0.020 115.734 -0.022
202112 -0.630 117.630 -0.693
202203 -0.520 121.301 -0.555
202206 -0.080 125.017 -0.083
202209 -0.430 125.227 -0.444
202212 -0.560 125.222 -0.579
202303 -0.490 127.348 -0.498
202306 -0.580 128.729 -0.583
202309 -0.520 129.860 -0.518
202312 -0.600 129.419 -0.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cara Therapeutics  (NAS:CARA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cara Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics (Cara Therapeutics) Business Description

Traded in Other Exchanges
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027